A THR-β agonist being developed by Madrigal for the treatment of MASH/NASH • Received its first approval on 14 March 2024 in the USA • Approved for use (under accelerated approval) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with F2 to F3 fibrosis) This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online.